Distinct COVID-19 vaccine combinations result in divergent immune responses

3

Luca M. Zaeck^{1*}, Nooc H. Tan^{2*}, Wim J.R. Rietdijk², Darvl Geers¹, Roos S.G. Sablerolles², 4 Susanne Bogers¹, Laura L.A. van Dijk¹, Lennert Gommers¹, Leanne P.M. van Leeuwen¹, 5 Sharona Rugebregt¹, Abraham Goorhuis^{3,4}, Douwe F. Postma⁵, Leo G. Visser⁶, Virgil A.S.H. 6 Dalm⁷, Melvin Lafeber⁸, Neeltje A. Kootstra⁹, Anke L.W. Huckriede¹⁰, Bart L. Haagmans¹, 7 8 Debbie van Baarle^{10,11}, Marion P.G. Koopmans¹, P. Hugo M. van der Kuy^{2#}, Corine H. GeurtsvanKessel^{1#\$}, Rory D. de Vries^{1#}, SWITCH-ON Research Group[%] 9 10 11 ¹ Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands 12 ² Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, the Netherlands 13 ³ Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University 14 Medical Centers, Amsterdam, the Netherlands 15 ⁴ Infection & Immunity, Amsterdam Public Health, University of Amsterdam, Amsterdam, the Netherlands ⁵ Department of Internal Medicine and Infectious Diseases, University Medical Center Groningen, Groningen, the 16 17 Netherlands 18 ⁶ Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands 19 ⁷ Department of Internal Medicine, Division of Allergy & Clinical Immunology and Department of Immunology, 20 Erasmus Medical Center, Rotterdam, the Netherlands 21 ⁸ Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands 22 ⁹ Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam Infection and 23 Immunity Institute, University of Amsterdam, Amsterdam, the Netherlands 24 ¹⁰ Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of 25 Groningen, Groningen, the Netherlands 26 ¹¹ Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the 27 Netherlands 28 29 * Contributed equally 30 [#] Contributed equally 31 [%] List of investigators from the SWITCH-ON research group is in **Supplementary Table S1** 32 33 ^{\$} corresponding author: Corine H. GeurtsvanKessel, department of Viroscience, Erasmus 34 35 Medical Center, Rotterdam, 3015 GD, Netherlands, c.geurtsvankessel@erasmusmc.nl 36

37 Summary

38 Waning antibody responses after COVID-19 vaccination combined with the emergence of the 39 SARS-CoV-2 Omicron lineage led to reduced vaccine effectiveness. As a countermeasure, 40 bivalent mRNA-based booster vaccines encoding the ancestral spike protein in combination 41 with that of Omicron BA.1 or BA.5 were introduced. Since then, BA.2-descendent lineages have 42 become dominant, such as XBB.1.5 or BA.2.86. Here, we assessed how different COVID-19 43 priming regimens affect the immunogenicity of the recently used bivalent booster vaccinations 44 and breakthrough infections. BA.1 and BA.5 bivalent vaccines boosted neutralizing antibodies 45 and T-cells up to 3 months after boost; however, cross-neutralization of XBB.1.5 was poor. Interestingly, different combinations of prime-boost regimens induced divergent responses: 46 47 participants primed with Ad26.COV2.S developed lower binding antibody levels after bivalent 48 boost while neutralization and T-cell responses were similar to mRNA-based primed 49 participants. In contrast, the breadth of neutralization was higher in mRNA-primed and bivalent 50 BA.5 boosted participants. Combined, we highlight important 'lessons learned' from the 51 employed COVID-19 vaccination strategies. Our data further support the use of monovalent 52 vaccines based on circulating strains when vaccinating risk groups, as recently recommended 53 by the WHO. We emphasize the importance of the continuous assessment of immune 54 responses targeting circulating variants to guide future COVID-19 vaccination policies.

55

56 Keywords

57 COVID-19, vaccination, SARS-CoV-2, neutralizing antibodies, immunity, bivalent vaccine, 58 adenovirus, mRNA.

60 Introduction

61 Vaccination against coronavirus disease-2019 (COVID-19) provides protection against infection, hospitalization, and mortality^{1,2}. However, ongoing waning of severe acute respiratory syndrome 62 63 coronavirus-2 (SARS-CoV-2)-specific immune responses and the continuous evolution of antigenically distinct variants result in an overall reduction of vaccine effectiveness³. The 64 currently circulating Omicron BA.2-descendent variants such as XBB.1.5 are the most immune 65 66 evasive to date⁴⁻⁶. This leads to an ongoing arms race: adapted vaccines are required to retain 67 effective protection on a population level, especially in vulnerable at-risk patients, in the face of 68 new emerging variants. As a countermeasure, mRNA-based bivalent vaccines incorporating an 69 Omicron BA.1 or BA.5 spike (S) protein in combination with the ancestral S were introduced in 70 2022^{7,8}.

71

72 While mRNA-based vaccines, including BNT162b2 and mRNA-1273, were initially shown to 73 have higher vaccine efficacy over adenovirus-vectored vaccines (Ad26.COV2.S and ChAdOx1-S) in a primary vaccination series^{3,9}, it is not known whether the different original priming 74 75 regimens have a long-lasting imprinting effect on the magnitude, durability, or breadth of the SARS-CoV-2-specific immune response¹⁰. Heterologous COVID-19 vaccination with different 76 77 vaccine platforms but the same S antigen was demonstrated to be at least non-inferior 78 regarding immunogenicity when compared to homologous priming with either mRNA-based or adenovirus-based vaccines alone¹¹⁻¹³. Shaping of the immune response as a consequence of 79 exposure to different S antigens was mostly studied in the context of hybrid immunity, a 80 81 combination of vaccination and infection. These studies showed evidence for serological 82 imprinting to the ancestral S protein, but also the induction of variant-specific immune responses¹⁴⁻¹⁶. 83

The SWITCH-ON trial^{17,18} aimed to evaluate the mRNA-based bivalent BA.1 and BA.5 booster 85 86 vaccines developed by Pfizer (BNT162b2) or Moderna (mRNA-1273.214 and mRNA-1273.222) 87 against the background of different priming regimens (mRNA-based or adeno-based), by 88 addressing three crucial questions: (1) How immunogenic are Omicron BA.1 or BA.5 bivalent 89 booster vaccines? (2) Do BA.1 or BA.5 bivalent booster vaccines differ in the induction of broad 90 neutralizing antibody responses, including adequate neutralization of XBB-descendent variants? 91 (3) How do immune responses among different original priming vaccination regimens evolve 92 over time and what can we learn for the future?

- 93
- 94 Results
- 95

96 Study design and baseline characteristics

97 A total of 434 healthcare workers (HCW) were included in the SWITCH-ON trial after screening 98 of 592 potential participants (Figure 1, baseline characteristics in Supplementary Tables S2 99 and S3). HCW received either Ad26.COV2.S or an mRNA-based (mRNA-1273 or BNT162b2) 100 priming vaccination regimen, followed by at least one mRNA-based booster vaccination before 101 inclusion in this study. The SWITCH-ON trial comprised two groups to which the participants 102 were randomly assigned: (1) a direct boost group (DB) (n=219, accounting for dropouts) or (2) a 103 postponed boost (PPB) group (n=183, accounting for dropouts). Participants in the DB group 104 were vaccinated in October 2022 with an Omicron BA.1 bivalent vaccine (BNT162b2 Omicron 105 BA.1 or mRNA-1273.214); participants in the PPB group were vaccinated in December 2022 106 with an Omicron BA.5 bivalent vaccine (BNT162b2 Omicron BA.5 or mRNA-1273.222). 107 Samples were collected before bivalent vaccination, at 7 and 28 days post-vaccination, and at 108 approximately 3 months post-vaccination (Supplementary Figure S1). No formal statistical 109 tests were performed to test for differences within or between groups as we deviated from the 110 original protocol in terms of pre-specified outcomes and a lower than anticipated sample size¹⁸.

111

112 Bivalent COVID-19 vaccines induce antibody and T-cell responses

The immunogenicity of Omicron BA.1 bivalent vaccines up to 28 days post-vaccination in the 113 114 SWITCH-ON trial was reported previously¹⁷. Both S-specific IgG binding and neutralizing 115 antibodies targeting ancestral SARS-CoV-2 increased within the first 28 days, with most of the 116 increase occurring between day 0 and 7 (Figure 2a,b). S-specific T-cell responses increased 117 rapidly in the first 7 days post-vaccination and subsequently waned (Figure 2c). At 3 months 118 post-vaccination, all of the measured immune parameters had decreased in comparison to the 119 previous study visit. Whereas antibodies did not yet wane to baseline levels, T-cell responses 120 returned close to baseline. The magnitude and kinetics of antibody and T-cell responses 121 induced by Omicron BA.5 bivalent booster vaccination were comparable to Omicron BA.1 122 bivalent boost, again with most of the increase occurring within the first 7 days (Figure 2d-f). 123 Overall, a comparable boost of (neutralizing) antibody and T-cell responses against ancestral 124 SARS-CoV-2 was observed after either Omicron BA.1 or BA.5 bivalent boost, independent of 125 the timing of vaccine administration.

126

127 mRNA-based priming leads to higher binding antibody levels after bivalent boost

128 The two groups (DB, Omicron BA.1 bivalent boost; PPB, Omicron BA.5 bivalent boost) could 129 each be subdivided into four subgroups, based on different priming and bivalent booster 130 regimens: (1) Ad26.COV2.S prime and mRNA-1273.214 or mRNA-1273.222 boost, (2) 131 Ad26.COV2.S prime and BNT162b2 Omicron BA.1 or BA.5 boost, (3) mRNA (mRNA-1273 or 132 BNT162b2)-based prime and mRNA-1273.214 or mRNA-1273.222 boost, and (4) mRNA-based 133 prime and BNT162b2 BA.1 or BA.5 boost (Supplementary Figure S1). Notably, Omicron BA.1-134 and BA.5-boosted participants who had previously received an mRNA-based priming 135 vaccination regimen consistently had higher levels of S-specific binding antibodies than those 136 who received an Ad26.COV2.S priming (Figure 3a,b, compare green and blue to red and

137 yellow). This effect of the original priming was not observed for ancestral SARS-CoV-2 138 neutralizing antibodies or T-cell responses (**Supplementary Figure S2**). Of specific interest, 139 bivalent booster vaccination with mRNA-1273.214 or mRNA-1273.222 resulted in a larger 140 increase of binding and neutralizing antibodies than boosting with their BNT162b2 counterparts 141 did, indicating that these vaccines are more immunogenic (**Figure 3** and **Supplementary** 142 **Figure S3**). Both findings underline that different prime-boost regimens lead to divergent 143 immune responses.

144

145 mRNA-based prime followed by BA.5 bivalent boost leads to broad neutralization

146 Neutralizing antibodies against relevant Omicron variants BA.1 and BA.5 (encoded by the 147 vaccines), and XBB.1.5 (circulating) were measured to assess the breadth of the neutralization 148 response (Figure 4a,b). Comparable to ancestral SARS-CoV-2 neutralization, Omicron BA.1 149 and BA.5 neutralization were boosted by both the BA.1 and BA.5 bivalent booster vaccines; 150 however, levels remained below those for ancestral SARS-CoV-2 neutralization at all 151 timepoints. At 3 months post-vaccination, waning of neutralizing antibodies was observed. 152 Remarkably, when correlating ancestral- and variant-specific neutralizing antibody titers 153 (Supplementary Figure S4), it was clear that waning of Omicron BA.1 and BA.5 neutralizing 154 antibodies occurred at a slower rate compared to ancestral SARS-CoV-2 neutralizing 155 antibodies. This was true for both individuals boosted with the bivalent Omicron BA.1 (Figure 156 4c,e) or BA.5 vaccine (Figure 4d,f). The circulating Omicron XBB.1.5 was poorly cross-157 neutralized at 3 months after bivalent boost, irrespective of the different prime-boost regimens 158 (Figure 4a,b). In participants boosted with the bivalent Omicron BA.5 vaccine, a preferential 159 boost of Omicron BA.5 neutralization was observed. This was not the case for Omicron BA.1 160 neutralizing antibodies in participants boosted with the bivalent Omicron BA.1 vaccine (Figure 161 **4g**, compare orange with purple radar plot). When subdividing participants boosted with bivalent 162 Omicron BA.5 in their respective prime-boost regimens, preferential boosting of Omicron BA.5

neutralization was restricted to participants who were primed with an mRNA-based vaccine
(Figure 4h). Participants primed with Ad26.COV2.S retained a narrow neutralizing response,
despite receiving the bivalent Omicron BA.5 booster.

166

167 Breakthrough infections lead to comparatively low levels of immune responses

168 In the PPB group, which was included in September 2022 but scheduled to receive the bivalent 169 Omicron BA.5 vaccine in December 2022, 13 test-confirmed infections were detected before 170 administration of the booster dose (Figure 5a). These participants were subsequently excluded 171 from the vaccine trajectory and analyzed separately as part of a natural infection-related sub-172 study. Breakthrough infection before bivalent vaccination boosted S-specific binding antibodies 173 and T-cell responses. However, binding antibody levels 7 days (GMT 3,655 BAU/mL [95% CI 174 2,167-6,166]) and 28 days (GMT 5,025 BAU/mL [95% CI 3,264-7,737]) post-infection (Figure 175 **5b**) were considerably lower than compared to the same time interval post-vaccination (7d: 176 GMT 10,503 BAU/mL [95% CI 9,218-11,969]; 28d: GMT 12,814 BAU/mL [95% CI 11,271-177 14,569], shown in Figure 2d). T-cell responses and Omicron neutralizing antibodies were 178 comparable to post-vaccination responses, although T-cell responses returned to baseline 179 faster compared to post-vaccination (Figure 5c,d). In addition, 59 breakthrough infections after 180 administration of either bivalent Omicron BA.1 or BA.5 booster vaccination were detected 181 through various methods (test-confirmed or detection of nucleocapsid-specific antibodies). Of 182 these participants, samples collected prior to infection were included in the preceding 183 immunogenicity analyses. Notably, breakthrough infection after Omicron BA.1 or BA.5 bivalent 184 boost did not result in an additional increase of antibody or T-cell responses in comparison to 185 the already vaccine-induced levels (Supplementary Figure S5). Overall, breakthrough 186 infections before and after vaccination were comparatively poorly immunogenic compared to 187 vaccine-induced immune responses.

189 Discussion

Here, we report that Omicron BA.1 or BA.5 bivalent booster vaccination results in rapid recall of humoral and cellular immune responses, which wane at 3 months post-vaccination. By simultaneously assessing multiple immune parameters, we found divergent immune responses after distinct COVID-19 vaccination regimens.

194

195 The immunogenicity and boosting of SARS-CoV-2-specific immune responses by Omicron BA.1 or BA.5 bivalent vaccination was in line with previous studies^{7,17,19}. As published vaccination 196 197 trials often do not take original priming vaccination regimens into account, no studies to our 198 knowledge have assessed bivalent vaccine immunogenicity in the context of different priming 199 regimens. Here, we find two important differences between bivalent-boosted participants primed 200 with either Ad26.COV2.S or an mRNA-based vaccine: (1) mRNA-based priming leads to higher 201 antibody levels upon boost, and (2) BA.5-bivalent boost only led to broad neutralization profiles 202 in mRNA-primed participants. This could be related to biological differences between the 203 vaccine platforms, as it was already shown that the vaccine effectiveness for adenovirus-204 vectored vaccines was lower compared to mRNA-based vaccines^{3,9}

205

206 When zooming in on the booster vaccines, mRNA-1273.214 and mRNA-1273.222 proved more 207 immunogenic than their BNT162b2 Omicron BA.1 and BA.5 counterparts. This supports a 208 recent Moderna-funded retrospective cohort study, which reported a greater effectiveness of 209 mRNA-1273.222 compared with BNT162b2 Omicron BA.5 in preventing COVID-19-related hospitalizations and outpatient visits²⁰. The differences in immunogenicity and efficacy between 210 211 the Pfizer and Moderna vaccines are likely explained by differences in dose and/or antigen 212 design. At 3 month post-bivalent booster vaccination, we uniformly observed waning of all measured immune parameters, consistent with previous reports^{21,22}. Interestingly, Omicron BA.1 213 214 and BA.5 neutralizing antibodies waned slower compared to ancestral SARS-CoV-2 neutralizing

antibodies after bivalent boost. The number of antigen exposures could be underlying this
 observation; repeated exposure is thought to boost antibodies of the IgG4 subclass, potentially
 affecting functionality²³.

218

219 Neutralizing antibodies are assumed to be the immunological correlate of protection against symptomatic SARS-CoV-2 infection⁹ and severe disease²⁴. Based on this assumption, 'variant-220 221 modified' booster vaccinations were predicted to offer an elevated level of protection²⁵. While the overall effectiveness of Omicron bivalent vaccination has been described^{20,26-28}, we show 222 223 that the cross-neutralization of the circulating BA.2-descendent Omicron variant XBB.1.5 was 224 poor after administration of either the Omicron BA.1 or the BA.5 bivalent booster vaccine, in line with previous reports⁴⁻⁶. It was recently demonstrated via receptor-binding domain (RBD) 225 226 depletion experiments that the immune response following an Omicron BA.5 bivalent booster 227 vaccination is primarily ancestral-specific and only cross-reactive towards BA.5, and that the concentrations of BA.5-specific antibodies are low²⁹. This is in line with a report that spike-228 229 binding monoclonal antibodies derived memory B-cells isolated from individuals boosted with 230 variant-modified mRNA vaccines (Beta/Delta bivalent or Omicron BA.1 monovalent) 231 predominantly recognized the ancestral SARS-CoV-2 spike protein, with only a low frequency of de novo B-cells targeting variant-specific epitopes³⁰. Similarly, induction of new antibody 232 233 responses from naïve B cells was shown to be suppressed after sequential homologous boosting¹⁵. As demonstrated by the low XBB.1.5 neutralizing antibody levels at 3 month post-234 235 bivalent booster independent of the prime-boost regimen, it is logical to assume that these 236 antibodies are even less cross-reactive with potential future lineages that are antigenically even 237 more distinct^{31,32}. Their reliance on the *de novo* induction of antigen-specific B cells to maintain 238 vaccine effectiveness may be even larger. Consequently, this argues in favor of employing 239 monovalent vaccines based on emerging lineages in subsequent vaccination campaigns, as recently recommended by the WHO³³. 240

241

242 The immunogenicity of SARS-CoV-2 breakthrough infections in comparison to booster 243 vaccinations has not been extensively studied. Although we had a relatively small study size, 244 and the variation between participants who had a breakthrough infection was large, we did find 245 that breakthrough infections appear not as immunogenic as vaccination. In participants that had 246 been enrolled but not yet vaccinated, a comparatively low boost of antibodies and rapidly 247 waning boost of T-cell responses was detected upon breakthrough. Furthermore, in participants 248 that had been vaccinated between 28 days and 3 months prior, no additional boost in S-specific 249 responses was detected upon breakthrough, likely because antibody and T-cell responses were 250 already relatively high. However, we only measured S-specific responses: breakthroughs could 251 have potentially boosted immune responses to other antigens. Additionally, it is unknown how 252 breakthrough infections with a variant effect protection from future infections.

253

254 Combined, our data emphasize important 'lessons learned' from the COVID-19 pandemic and 255 associated vaccination strategies: (1) the original priming vaccination has an imprinting effect on 256 the immune system that can still be observed after at least two mRNA-based booster vaccines, 257 and (2) not all mRNA-based booster vaccines are equally immunogenic; in the SWITCH-ON trial 258 only bivalent Omicron BA.5 vaccination broadened the neutralizing antibody response, whereas 259 the bivalent BA.1 vaccine did not. Our data support the recent vaccination advice from the WHO (as of May 2023)³³ to vaccinate risk groups with monovalent vaccines based on the circulating 260 261 XBB.1-descendent lineage, as the current (bivalent) vaccines only induce limited cross-262 neutralization. Our data emphasize the importance to continuously evaluate immune responses 263 and cross-reactivity with circulating variants to guide future COVID-19 vaccination policy 264 making.

265

266 Methods

267

268 Study design and participants

The SWITCH-ON study is an ongoing multicenter, open-label, randomized controlled trial, which was conducted in accordance with the Declaration of Helsinki. Participants were randomized to either the direct boost group (DB) or the postponed boost group (PPB), who received a booster vaccination with an Omicron BA.1 or BA.5 bivalent vaccine in October or December 2022, respectively. This article reports the data for both study groups covering the period from the day of booster vaccination until 3 months post-vaccination. All participants involved in the study have given written informed consent prior to the first study visit.

276

277 HCW between the age of 18 to 65 years were invited to join the SWITCH-ON trial from four 278 academic hospitals in the Netherlands (Amsterdam University Medical Center, Erasmus Medical 279 Center, Leiden University Medical Center, and University Medical Center Groningen). Eligible 280 participants were primed with either one/two dose(s) of adenovirus-based (Ad26.COV2.S) or 281 two doses of mRNA-based vaccine (BNT162b2 or mRNA-1273), and have received at least one 282 mRNA-based booster. Prior SARS-CoV-2 infections were allowed; however, the last booster 283 vaccination or SARS-CoV-2 infection had to have occurred at least 12 weeks before the bivalent 284 booster was due, as per advised interval between boosts from the National Institute for Public Health and the Environment (RIVM)³⁴. Infection history was collected through a self-reported 285 286 questionnaire. The full list of inclusion and exclusion criteria can be found in the study protocol¹⁸. 287

288

289 Randomization and masking

All eligible participants were randomized using Castor software to the DB (Omicron BA.1 bivalent boost) or PPB (Omicron BA.5 bivalent boost) group in a 1:1 ratio by block

randomization with block sizes of 16 and 24. Due to the set-up of the study, it was not possible to blind participants from randomization. Therefore, participants were informed about their group allocation prior to the first study visit. Randomization was completed by research assistants who were not involved in statistical analyses. Laboratory personnel were not masked from randomization allocations.

297

298 Procedures

299 Participants in the DB group received an Omicron BA.1 bivalent booster in October 2022. If 300 participants were younger than 45 years old, BNT162b2 Omicron BA.1 was administered; 301 mRNA-1273.214 was administered to participants 45 years and older. This age division was introduced as per advice from the RIVM³⁴. Following consultation with the RIVM, the age 302 303 division was removed for the PPB group, and participants were randomized to receive the 304 Omicron bivalent booster vaccination with either BNT162b2 Omicron BA.5 or mRNA-1273.222. 305 In both groups, blood was taken during the first study visit (study visit 1, day 0). Additional blood 306 samples were collected in subsequent study visits: study visit 2 (day 7 \pm 1 days after boost), 307 study visit 3 (day 28 ± 2 days after boost) and study visit 4 (day 90 ± 14 days after boost).

308

A baseline characteristics questionnaire was obtained after randomization to collect information about year of birth, biological sex, height, weight, ancestry, occupation, history of SARS-CoV-2 infection, and history of COVID-19 vaccination. A few days prior to each study visit, participants received a questionnaire to detect SARS-CoV-2 infections between the last and upcoming study visit. Via this infection questionnaire, we could identify participants who had an infection during the course of the study.

(1) If the infection occurred between the informed consent session and the first vaccination
 study visit, participants were invited to join a sub-study to analyze immunological
 response after natural infection and they would be excluded from vaccination trajectory.

318 In this sub-study, blood samples would be collected at 7 and 28 days after participants 319 tested positive (by at-home antigen test) for COVID-19 (**Figure 5**).

- (2) If the infection occurred between baseline and day 28 post-vaccination, no additional
 blood samples were taken as the mixed effect of natural infection and vaccination would
 be difficult to distinguish. These participants were excluded from all analyses.
- (3) If the infection occurred between study visits day 28 and 3 months post-vaccination,
 participants would be invited for additional blood sampling on day 7 and 28 after they
 had tested positive, and remained in the study. Samples collected prior to infection were
 included in the immunogenicity analysis (Supplementary Figure 5).
- 327

328 Outcomes

329 According to the study protocol, the primary outcome was the fold change (i.e., geometric mean 330 ratio [GMR]) in antibody response between baseline and 28 days after boost across both 331 groups. Secondary outcomes were fast response, S-specific T-cell response and levels of neutralizing antibodies^{17,18}. Here, we report observational data on magnitude and quality of the 332 333 immunological response. Therefore, a descriptive approach was used to describe the immunogenicity of bivalent booster vaccinations over the period of 3 months following 334 335 vaccination. We measured S-specific IgG binding antibodies, S-specific T-cell responses, and 336 neutralization of the ancestral, BA.1, BA.5, and XBB.1.5 variants. Similar parameters were 337 analyzed in the infection sub-study.

338

339 Identification of recent SARS-CoV-2 infection

Infections were either identified via self-reporting of participants following a positive test result in
 an at-home antigen test, or the detection of SARS-CoV-2 nucleocapsid (N)-specific antibodies.
 N-specific antibodies were measured at baseline and at 3 month post-boost using the Abbott
 SARS-CoV-2 IgG assay following the manufacturer's instructions. N-specific antibody levels

were expressed in a signal-to-cutoff (S/CO) ratio and the manufacturer-recommended cut-off for positivity of \geq 1.4 S/CO was used. If a participants had detectable N-specific antibodies at 3 month post-boost, the other timepoints at 7 and 28 days post-boost were also tested to narrow down the moment of infection. All samples from the timepoint N-specific antibodies were detectable (or increased at least two-fold) and onwards were excluded from the immunogenicity analyses of bivalent booster vaccinations.

350

351 Detection of SARS-CoV-2 S1-specific IgG antibodies

S1-specific antibodies were measured as previously described³⁵, by Liaison SARS-CoV-2
 TrimericS IgG assay (DiaSorin). The lower limit of detection (LLoD) was 4.81 BAU/mL and the
 cut-off for positivity was 33.8 BAU/mL, according to manufacturer's instructions.

355

356 Detection of SARS-CoV-2 neutralizing antibodies

357 Serum samples were tested for the presence of neutralizing antibodies against ancestral SARS-358 CoV-2, and the Omicron BA.1, BA.5, and XBB.1.5 variants in a plaque reduction neutralization test (PRNT) as previously described¹⁷. Viruses were cultured from clinical material and 359 360 sequences were confirmed by next-generation sequencing: D614G (ancestral; GISAID: hCov-361 19/Netherlands/ZH-EMC-2498), Omicron BA.1 (GISAID: hCoV-19/Netherlands/LI-SQD-362 01032/2022), Omicron BA.5 (EVAg: 010V-04723; hCovN19/Netherlands/ZHNEMCN5892), and 363 Omicron XBB.1.5 (GISAID: hCov-19/Netherlands/NH-EMC-5667). The human airway Calu-3 364 cell line (ATCC HTB-55) was used to grow virus stocks and to conduct PRNT. Calu-3 cells were 365 cultured in OptiMEM supplemented with GlutaMAX (Gibco), penicillin (100 units/mL, Capricorn 366 Scientific), streptomycin (0.1 mg/mL, Capricorn Scientific), and 10% fetal bovine serum (FBS; 367 Sigma). Briefly, heat-inactivated sera were diluted two-fold serially diluted in OptiMEM without 368 FBS. The dilutions ranges were based on the respective variant and the S-specific binding 369 antibody level: ancestral SARS-CoV-2 (<1,500 BAU/mL: 1:10 - 1:1,280; 1,500 - 6,000 BAU/mL:

370 1:80 - 1:10.240; >6.000 BAU/mL: 1:640 - 1: 81.920), Omicron BA.1/BA.5 variants (<6.000 BAU/mL: 1:10 - 1:1280; >6,000 BAU/mL: 1:80 - 1: 10,240), Omicron XBB.1.5 variant (<6,000 371 372 BAU/mL: 1:10 – 1:1280; >6,000 BAU/mL: 1:40 – 1: 5,120). Four hundred PFU of either SARS-373 CoV-2 variant in an equal volume of OptiMEM medium were added to the diluted sera and 374 incubated at 37°C for 1 hour. The antibody-virus mix was then transferred to Calu-3 cells and 375 incubated at 37°C for 8 hours. Afterwards, the cells were fixed in 10% neutral-buffered formalin, 376 permeabilized in 70% ethanol, and the plaques stained with a polyclonal rabbit anti-SARS-CoV-377 2 nucleocapsid antibody (Sino Biological) and a secondary peroxidase-labeled goat-anti rabbit 378 IgG antibody (Dako). The signals were developed with a precipitate-forming TMB substrate 379 (TrueBlue: SeraCare/KPL) and the number of plagues per well was guantified with an 380 ImmunoSpot Image Analyzer (CTL Europe GmbH). The 50% reduction titer (PRNT50) was 381 estimated by calculating the proportionate distance between two dilutions from which the 382 endpoint titer was calculated. An infection control (without serum) and positive serum control 383 (Nanogam® 100 mg/mL, Sanquin) were included on every assay plate. When no neutralization 384 was observed, the PRNT50 was assigned a value of 10.

385

386 **Detection of T-cell responses by interferon gamma release assay (IGRA)**

387 The SARS-CoV-2-specific T-cell response was quantified using an interferon gamma (IFN-y) 388 release assay (IGRA) in whole blood using the commercially available QuantiFERON SARS-CoV-2 assay kit (QIAGEN) as previously described¹¹. The assay kit is certified for *in vitro* 389 390 diagnostic (IVD) use. Heparinized whole blood was incubated with three different SARS-CoV-2 391 antigens for 20 – 24 h using a combination of peptides stimulating both CD4+ and CD8+ T-cells 392 (Ag1, Ag2, Ag3). Mitogen- and carrier (NIL)-coated control tubes were included as positive 393 control and negative control, respectively. After incubation, plasma was obtained by 394 centrifugation, and IFN-y production in response to antigen stimulation was measured by ELISA 395 (QuantiFERON SARS-CoV-2 ELISA Kit [certified for IVD use]; QIAGEN). Results were

expressed in international units (IU) IFN-γ/mL after subtraction of the NIL control values as
interpolated from a standard calibration curve. LLoD was 0.01 IU/mL and the responder cut-off
was 0.15 IU/mL, according to the manufacturer's instructions. Only data obtained with Ag2
(overlapping peptides covering the ancestral S protein) is shown in this manuscript.

400

401 Statistical analysis

402 A power calculation in the SWITCH-ON trial was performed to identify the number of 403 participants required per study arm, namely: (i) Ad26.COV2.S prime in the DB group, (ii) mRNA-404 based prime in the DB group, (iii) Ad26.COV2.S prime in the PPB group and (iv) mRNA-based 405 prime in the PPB group. For each arm, 91 participants were required to reach 80% power at a 406 two-sided 5% significance level to detect a difference of 0.2 log10-transformed in the fold 407 change of antibody response between vaccination day and 28 days after boost. This difference was based on the previous HCW study performed at Erasmus MC³⁵, in which the mean fold 408 409 changes for adenovirus-primed participants and mRNA-primed participants were reported as 410 1.344 (SD 0.451) and 1.151 (0.449), respectively.

411

412 A descriptive analysis was used to report baseline characteristics of participants. For continuous 413 variables, mean and standard deviation (SD) were reported if the data have normal distribution. 414 Otherwise, median and interguartile range (IQR) were used for data with non-normal 415 distribution. Count and percentages were used to report categorical variables. For missing 416 values, no imputation was performed and data availability was reported in Supplementary 417 Table S4. Immunological data were reported as geometric mean titers or geometric means and 418 95% confidence intervals. Spearman correlations were reported in **Supplementary Figure S4**. 419 No formal statistical tests were performed to test for differences within or between groups as we 420 deviated from the original protocol in terms of pre-specified outcomes and a lower than size¹⁸ 421 anticipated sample

422 Acknowledgements

No private funding was received for these studies. The bivalent BA.5 vaccine mRNA-1273.222 423 424 was provided by Moderna. Moderna reviewed the final version of the manuscript, but had no 425 role in study design, data collection, data analysis, data interpretation, or writing of the report. All 426 other vaccines were supplied by the Center for Infectious Disease Control, National Institute for 427 Public Health and the Environment, the Netherlands (RIVM). Cohort images were created with 428 BioRender. This study was funded by the Netherlands Organization for Health Research and 429 Development (ZonMw), grant agreement 10430072110001. The funder of the study had no role 430 in study design, data collection, data analysis, data interpretation, or writing of the report.

431

432 Author contributions statement

PHMvdK, CHGvK, and RDdV conceptualized the trial. LMZ, NHT, WJRR, DG, and RDdV
performed the formal analysis. NHT, WJRR, RSGS, AG, DFP, LGV, VASHD, ML, NAK, ALWH,
DvB, MPGK, PHMvdK, CHGvK, and RDdV acquired funding. All authors were involved in the
investigation. LMZ, NHT, PHMvdK, CHGvK, and RDdV performed project administration. AG,
DFP, LGV, PHMvdK, CHGvK, and RDdV supervised the trial. RDdV visualized the results. LMZ,
NHT, PHMvdK, CGvK, and RDdV wrote the original draft of the manuscript. All authors
reviewed and edited the final version of the manuscript.

440

441 **Competing interests**

442 We declare no competing interests.

443

444 Data availability

Data from the present study are not part of public databases but are available upon reasonable request from the corresponding author. Materials and samples are available upon reasonable request, will be released via a material transfer agreement and can otherwise be obtained via

- 448 the included experimental protocols. The SARS-CoV-2 virus stocks are available through the
- 449 European Virus Archive Global.
- 450

451 Code availability

- 452 No specific code was written or generated for analysis of the data. Software use has been
- 453 disclosed.
- 454

455 Figures



Figure 1. SWITCH-ON trial enrollment. A total of 592 healthcare workers (HCW) were screened for eligibility, of whom 434 were included and randomized 1:1 to the direct boost (n = 219) and the postponed boost (n = 215) group. Following dropouts, a total of 183 HCW received an Omicron BA.5 bivalent vaccine in the postponed group.

461



463 Figure 2. Antibody and T-cell responses after bivalent booster vaccination. a-f, Detection 464 of (ancestral) spike (S)-specific binding IgG antibodies (a,d), ancestral SARS-CoV-2 neutralizing 465 antibodies (b,e), and T-cell responses measured by interferon-gamma (IFN-y) release assay 466 (IGRA) (c,f) after Omicron BA.1 (a-c) or BA.5 (d-f) bivalent booster vaccination at baseline, and 467 7 days, 28 days, and 3 months post-boost. Colors indicate the specific prime-boost regimen (red 468 = Ad26.COV2.S prime, mRNA-1273.214 or mRNA-1273.222 boost; yellow = Ad26.COV2.S 469 prime, BNT162b2 Omicron BA.1 or BA.5 boost; green = mRNA-based prime, mRNA-1273.214 470 or mRNA-1273.222 boost; blue = mRNA-based prime, BNT162b2 Omicron BA.1 or BA.5 boost). 471 Data are shown in box-and-whisker plots, with the horizontal lines indicating the median, the 472 bounds of the boxes indicating the IQR, and the whiskers indicating the range. Bold numbers 473 above the plots represent the respective geometric mean (titer) per timepoint. The line graphs 474 next to each panel depict a time course of the respective geometric mean values with 95% 475 confidence intervals.

476



Figure 3. Antibody and T-cell responses after different original priming and bivalent 478 479 **booster vaccinations.** a,b, Detection of S-specific binding IgG antibody levels in subgroups 480 based on the different combinations original priming regimen after Omicron BA.1 (a) or BA.5 (b) 481 bivalent booster vaccination at baseline, and 7 days, 28 days, and 3 months post-boost (red = 482 Ad26.COV2.S prime, mRNA-1273.214 or mRNA-1273.222 boost; yellow = Ad26.COV2.S prime, 483 BNT162b2 Omicron BA.1 or BA.5 boost; green = mRNA-based prime, mRNA-1273.214 or 484 mRNA-1273.222 boost; blue = mRNA-based prime, BNT162b2 Omicron BA.1 or BA.5 boost). 485 Data are shown in box-and-whisker plots, with the horizontal lines indicating the median, the 486 bounds of the boxes indicating the IQR, and the whiskers indicating the range. Bold numbers 487 above the plots represent the respective geometric mean (titer) per timepoint. The line graphs 488 next to each panel depict a time course of the respective geometric mean values with 95% 489 confidence intervals.



492 **Figure 4. Breadth of the neutralizing antibody response after bivalent booster** 493 **vaccination. a,b**, Detection of neutralizing antibodies targeting ancestral SARS-CoV-2 and

494 Omicron BA.1, BA.5, and XBB.1.5 variants after Omicron BA.1 (a) or BA.5 (b) bivalent booster 495 vaccination at baseline, and 7 days, 28 days, and 3 months post-boost. Colors indicate the 496 specific prime-boost regimen (red = Ad26.COV2.S prime, mRNA-1273.214 or mRNA-1273.222 497 boost; yellow = Ad26.COV2.S prime, BNT162b2 Omicron BA.1 or BA.5 boost; green = mRNA-498 based prime, mRNA-1273.214 or mRNA-1273.222 boost; blue = mRNA-based prime, 499 BNT162b2 Omicron BA.1 or BA.5 boost). c-f, Correlation between PRNT50 titers against 500 ancestral SARS-CoV-2 and the Omicron BA.1 (c,d) or BA.5 (e,f) variants over time after 501 Omicron BA.1 (c,e) or BA.5 (d,f) vaccination at baseline, and 7 days, 28 days, and 3 months 502 post-boost. Colored symbols indicate the specific timepoints (yellow = baseline [0 d]; teal = 7 d; 503 purple = 28 d; orange = 77 d [c,e]/98 d [d,f]). The arrows connect the correlated geometric 504 means (+ 95% CI) per timepoint and visualize the neutralization kinetics. g,h, Spiderweb plots 505 depicting the variant-specific PRNT50 titers relative to ancestral SARS-CoV-2 neutralization (set 506 to 100%), after vaccination with bivalent Omicron BA.1 (g) or BA.5 (g,h). Data in panels a,b are 507 shown in box-and-whisker plots, with the horizontal lines indicating the median, the bounds of 508 the boxes indicating the IQR, and the whiskers indicating the range. Bold numbers above the 509 plots represent the respective geometric mean (titer) per timepoint. The line graphs next to each 510 panel depict a time course of the respective geometric mean values with 95% confidence 511 intervals.



514 Figure 5. Breadth of the neutralizing antibody response after breakthrough infection. a, 515 Sampling procedure for participants in the postponed boost group who had a breakthrough 516 infection before their intended vaccination with the bivalent Omicron BA.5 booster vaccine. They 517 were subsequently excluded from the vaccination trajectory and invited to participate in a sub-518 study on the immunogenicity of natural SARS-CoV-2 infection. Samples were collected 7 and 519 28 days after the participants tested positive. **b-d**, Detection of (ancestral) S-specific binding IgG 520 antibodies (b), T-cell responses measured by IGRA (c), and neutralizing antibodies targeting 521 ancestral SARS-CoV-2 and Omicron BA.1, BA.5, and XBB.1.5 variants (d) before, and 7 and 28 522 days after breakthrough infection, which was contracted before intended vaccination with the 523 bivalent Omicron BA.5 booster vaccine (red = Ad26.COV2.S prime; blue mRNA-based prime). 524 Data are shown in box-and-whisker plots, with the horizontal lines indicating the median, the 525 bounds of the boxes indicating the IQR, and the whiskers indicating the range. Bold numbers 526 above the plots represent the respective geometric mean (titer) per timepoint. The line graphs 527 next to each panel depict a time course of the respective geometric mean values with 95% 528 confidence intervals.

529 References

- 530 1. Watson, O.J., Barnsley, G., Toor, J., Hogan, A.B., Winskill, P., and Ghani, A.C. (2022).
- 531 Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.

532 Lancet Infect Dis 22, 1293-1302. 10.1016/S1473-3099(22)00320-6.

- 533 2. Suthar, A.B., Wang, J., Seffren, V., Wiegand, R.E., Griffing, S., and Zell, E. (2022).
- 534 Public health impact of covid-19 vaccines in the US: observational study. BMJ 377,
- 535 e069317. 10.1136/bmj-2021-069317.
- 536 3. Wu, N., Joyal-Desmarais, K., Ribeiro, P.A.B., Vieira, A.M., Stojanovic, J., Sanuade, C.,
- 537 Yip, D., and Bacon, S.L. (2023). Long-term effectiveness of COVID-19 vaccines against
- 538 infections, hospitalisations, and mortality in adults: findings from a rapid living systematic
- 539 evidence synthesis and meta-analysis up to December, 2022. Lancet Respir Med 11,

540 439-452. 10.1016/S2213-2600(23)00015-2.

- 541 4. Kurhade, C., Zou, J., Xia, H., Liu, M., Chang, H.C., Ren, P., Xie, X., and Shi, P.Y.
- 542 (2023). Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by
- 543 parental mRNA vaccine or a BA.5 bivalent booster. Nat Med 29, 344-347.
- 544 10.1038/s41591-022-02162-x.
- 545 5. Wang, Q., Iketani, S., Li, Z., Liu, L., Guo, Y., Huang, Y., Bowen, A.D., Liu, M., Wang, M.,
 546 Yu, J., et al. (2023). Alarming antibody evasion properties of rising SARS-CoV-2 BQ and
 547 XBB subvariants. Cell *186*, 279-286 e278. 10.1016/j.cell.2022.12.018.
- 548 6. Yue, C., Song, W., Wang, L., Jian, F., Chen, X., Gao, F., Shen, Z., Wang, Y., Wang, X.,
- and Cao, Y. (2023). ACE2 binding and antibody evasion in enhanced transmissibility of
- 550 XBB.1.5. Lancet Infect Dis 23, 278-280. 10.1016/S1473-3099(23)00010-5.
- 551 7. Chalkias, S., Harper, C., Vrbicky, K., Walsh, S.R., Essink, B., Brosz, A., McGhee, N.,
- 552 Tomassini, J.E., Chen, X., Chang, Y., et al. (2022). A Bivalent Omicron-Containing
- 553 Booster Vaccine against Covid-19. N Engl J Med 387, 1279-1291.
- 554 10.1056/NEJMoa2208343.

555	8.	Winokur, P., Gayed, J., Fitz-Patrick, D., Thomas, S.J., Diya, O., Lockhart, S., Xu, X.,
556		Zhang, Y., Bangad, V., Schwartz, H.I., et al. (2023). Bivalent Omicron BA.1-Adapted
557		BNT162b2 Booster in Adults Older than 55 Years. N Engl J Med 388, 214-227.
558		10.1056/NEJMoa2213082.
559	9.	Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A.,
560		Subbarao, K., Kent, S.J., Triccas, J.A., and Davenport, M.P. (2021). Neutralizing
561		antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-
562		2 infection. Nat Med 27, 1205-1211. 10.1038/s41591-021-01377-8.
563	10.	Zaeck, L.M., GeurtsvanKessel, C.H., and de Vries, R.D. (2023). COVID-19 vaccine
564		effectiveness and evolving variants: understanding the immunological footprint. Lancet
565		Respir Med 11, 395-396. 10.1016/S2213-2600(23)00140-6.
566	11.	Sablerolles, R.S.G., Rietdijk, W.J.R., Goorhuis, A., Postma, D.F., Visser, L.G., Geers,
567		D., Schmitz, K.S., Garcia Garrido, H.M., Koopmans, M.P.G., Dalm, V., et al. (2022).
568		Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming. N
569		Engl J Med 386, 951-963. 10.1056/NEJMoa2116747.
570	12.	Atmar, R.L., Lyke, K.E., Deming, M.E., Jackson, L.A., Branche, A.R., El Sahly, H.M.,
571		Rostad, C.A., Martin, J.M., Johnston, C., Rupp, R.E., et al. (2022). Homologous and
572		Heterologous Covid-19 Booster Vaccinations. N Engl J Med 386, 1046-1057.
573		10.1056/NEJMoa2116414.
574	13.	Hillus, D., Schwarz, T., Tober-Lau, P., Vanshylla, K., Hastor, H., Thibeault, C., Jentzsch,
575		S., Helbig, E.T., Lippert, L.J., Tscheak, P., et al. (2021). Safety, reactogenicity, and
576		immunogenicity of homologous and heterologous prime-boost immunisation with
577		ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med 9,

578 1255-1265. 10.1016/S2213-2600(21)00357-X.

579 14. Reynolds, C.J., Gibbons, J.M., Pade, C., Lin, K.M., Sandoval, D.M., Pieper, F., Butler,

580 D.K., Liu, S., Otter, A.D., Joy, G., et al. (2022). Heterologous infection and vaccination

581 shapes immunity against SARS-CoV-2 variants. Science *375*, 183-192.

582 10.1126/science.abm0811.

- 583 15. Schiepers, A., van 't Wout, M.F.L., Greaney, A.J., Zang, T., Muramatsu, H., Lin, P.J.C.,
- 584 Tam, Y.K., Mesin, L., Starr, T.N., Bieniasz, P.D., et al. (2023). Molecular fate-mapping of
- 585 serum antibody responses to repeat immunization. Nature *615*, 482-489.
- 586 10.1038/s41586-023-05715-3.
- 587 16. Baerends, E.A.M., Reekie, J., Andreasen, S.R., Staerke, N.B., Raben, D., Nielsen, H.,
- 588 Petersen, K.T., Johansen, I.S., Lindvig, S.O., Madsen, L.W., et al. (2023). Omicron
- 589 variant-specific serological imprinting following BA.1 or BA.4/5 bivalent vaccination and
- 590 previous SARS-CoV-2 infection: A cohort study. Clin Infect Dis. 10.1093/cid/ciad402.
- 591 17. Tan, N.H., Geers, D., Sablerolles, R.S.G., Rietdijk, W.J.R., Goorhuis, A., Postma, D.F.,
- 592 Visser, L.G., Bogers, S., van Dijk, L.L.A., Gommers, L., et al. (2023). Immunogenicity of
- 593 bivalent omicron (BA.1) booster vaccination after different priming regimens in health-
- 594 care workers in the Netherlands (SWITCH ON): results from the direct boost group of an
- 595 open-label, multicentre, randomised controlled trial. Lancet Infect Dis 23, 901-913.
- 596 10.1016/S1473-3099(23)00140-8.
- 597 18. Tan, N.H., Sablerolles, R.S.G., Rietdijk, W.J.R., Goorhuis, A., Postma, D.F., Visser,
- L.G., Bogers, S., Geers, D., Zaeck, L.M., Koopmans, M.P.G., et al. (2022). Analyzing the
 immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON
 trial protocol. Front Immunol *13*, 1067749. 10.3389/fimmu.2022.1067749.
- Collier, A.Y., Miller, J., Hachmann, N.P., McMahan, K., Liu, J., Bondzie, E.A., Gallup, L.,
 Rowe, M., Schonberg, E., Thai, S., et al. (2023). Immunogenicity of BA.5 Bivalent mRNA
 Vaccine Boosters. N Engl J Med *388*, 565-567. 10.1056/NEJMc2213948.
- 20. Kopel, H., Nguyen, V.H., Boileau, C., Bogdanov, A., Winer, I., Ducruet, T., Zeng, N.,
- Bonafede, M., Esposito, D.B., Martin, D., et al. (2023). Comparative Effectiveness of the
- Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and

607 BNT162b2 Bivalent in Adults in the United States. medRxiv.

- 608 10.1101/2023.07.12.23292576.
- 609 21. Chalkias, S., Harper, C., Vrbicky, K., Walsh, S., Essink, B., Brosz, A., McGhee, N.,
- 610 Tomassini, J., Chen, X., Chang, Y., et al. (2022). Three-month Antibody Persistence of a
- 611 Bivalent Omicron-containing Booster Vaccine Against COVID-19. Research Square.
- 612 10.21203/rs.3.rs-2239682/v1.
- 613 22. Favresse, J., Gillot, C., Closset, M., Cabo, J., Wauthier, L., David, C., Elsen, M., Dogné,
- 514 J.-M., and Douxfils, J. (2023). Durability of humoral and cellular immunity six months
- 615 after the BNT162b2 bivalent booster. Authorea. 10.22541/au.168983668.85960360/v1.
- 616 23. Irrgang, P., Gerling, J., Kocher, K., Lapuente, D., Steininger, P., Habenicht, K., Wytopil,
- 617 M., Beileke, S., Schafer, S., Zhong, J., et al. (2023). Class switch toward
- 618 noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA

619 vaccination. Sci Immunol *8*, eade2798. 10.1126/sciimmunol.ade2798.

- 620 24. Cromer, D., Steain, M., Reynaldi, A., Schlub, T.E., Khan, S.R., Sasson, S.C., Kent, S.J.,
- 621 Khoury, D.S., and Davenport, M.P. (2023). Predicting vaccine effectiveness against
- 622 severe COVID-19 over time and against variants: a meta-analysis. Nat Commun 14,
- 623 1633. 10.1038/s41467-023-37176-7.
- 624 25. Khoury, D.S., Docken, S.S., Subbarao, K., Kent, S.J., Davenport, M.P., and Cromer, D.

625 (2023). Predicting the efficacy of variant-modified COVID-19 vaccine boosters. Nat Med
626 29, 574-578. 10.1038/s41591-023-02228-4.

- 627 26. Andersson, N.W., Thiesson, E.M., Baum, U., Pihlstrom, N., Starrfelt, J., Faksova, K.,
- 628 Poukka, E., Meijerink, H., Ljung, R., and Hviid, A. (2023). Comparative effectiveness of
- bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged >/=50 years in
- 630 Nordic countries: nationwide cohort study. BMJ 382, e075286. 10.1136/bmj-2022-
- 631 075286.

632 27. Link-Gelles, R., Weber, Z.A., Reese, S.E., Payne, A.B., Gaglani, M., Adams, K.,

- 633 Kharbanda, A.B., Natarajan, K., DeSilva, M.B., Dascomb, K., et al. (2023). Estimates of
- 634 Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization
- 635 and Critical Illness Among Adults with and Without Immunocompromising Conditions -
- 636 VISION Network, September 2022-April 2023. MMWR Morb Mortal Wkly Rep 72, 579-
- 637 588. 10.15585/mmwr.mm7221a3.
- 638 28. Lin, D.Y., Xu, Y., Gu, Y., Zeng, D., Sunny, S.K., and Moore, Z. (2023). Durability of
- Bivalent Boosters against Omicron Subvariants. N Engl J Med 388, 1818-1820.
- 640 10.1056/NEJMc2302462.
- Carreno, J.M., Singh, G., Simon, V., Krammer, F., and group, P.V.I.s. (2023). Bivalent
 COVID-19 booster vaccines and the absence of BA.5-specific antibodies. Lancet
 Microbe. 10.1016/S2666-5247(23)00118-0.
- 644 30. Alsoussi, W.B., Malladi, S.K., Zhou, J.Q., Liu, Z., Ying, B., Kim, W., Schmitz, A.J., Lei,
- T., Horvath, S.C., Sturtz, A.J., et al. (2023). SARS-CoV-2 Omicron boosting induces de
- 646 novo B cell response in humans. Nature *617*, 592-598. 10.1038/s41586-023-06025-4.
- 647 31. Mykytyn, A.Z., Rosu, M.E., Kok, A., Rissmann, M., van Amerongen, G.,
- 648 Geurtsvankessel, C., de Vries, R.D., Munnink, B.B.O., Smith, D.J., Koopmans, M.P.G.,
- 649 et al. (2023). Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1,
- 650 BQ.1.1, and XBB.1. Lancet Microbe *4*, e294-e295. 10.1016/S2666-5247(22)00384-6.
- 32. Mykytyn, A.Z., Rissmann, M., Kok, A., Rosu, M.E., Schipper, D., Breugem, T.I., van den
- Doel, P.B., Chandler, F., Bestebroer, T., de Wit, M., et al. (2022). Antigenic cartography
- 653 of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct. Sci
- 654 Immunol 7, eabq4450. 10.1126/sciimmunol.abq4450.
- 655 33. World Health Organization (2023). Statement on the antigen composition of COVID-19
- 656 vaccines. <u>https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-</u>
- 657 <u>composition-of-covid-19-vaccines</u>.

- 658 34. RIVM (2023). Uitvoeringsrichtlijn COVID-19-vaccinatie.
- 659 <u>https://lci.rivm.nl/richtlijnen/covid-19-vaccinatie</u>.
- 660 35. GeurtsvanKessel, C.H., Geers, D., Schmitz, K.S., Mykytyn, A.Z., Lamers, M.M., Bogers,
- 661 S., Scherbeijn, S., Gommers, L., Sablerolles, R.S.G., Nieuwkoop, N.N., et al. (2022).
- 662 Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine
- recipients. Sci Immunol 7, eabo2202. 10.1126/sciimmunol.abo2202.